Burapitant: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Burapitant}} | |||
== | ==Overview== | ||
Burapitant is a | '''Burapitant''' is a chemical compound that acts as a [[neurokinin-1 receptor antagonist]]. It is primarily researched for its potential use in treating conditions such as [[nausea]] and [[vomiting]], particularly those induced by [[chemotherapy]]. | ||
== | ==Chemical Structure== | ||
Burapitant is | [[File:Burapitant_structure.png|thumb|right|Chemical structure of Burapitant]] | ||
Burapitant is characterized by its unique chemical structure, which allows it to effectively bind to and inhibit the [[neurokinin-1 receptor]]. This receptor is involved in the body's response to stress and pain, making Burapitant a compound of interest in the development of new therapeutic agents. | |||
== | ==Mechanism of Action== | ||
Burapitant works by blocking the action of [[substance P]], a neuropeptide that binds to the neurokinin-1 receptor. By inhibiting this interaction, Burapitant can reduce the symptoms associated with [[emesis]] and potentially other conditions mediated by substance P. | |||
== | ==Potential Applications== | ||
Burapitant | The primary application of Burapitant is in the management of [[chemotherapy-induced nausea and vomiting]] (CINV). It may also have potential uses in treating other conditions where substance P is implicated, such as certain types of [[pain]] and [[depression]]. | ||
== | ==Research and Development== | ||
Research into Burapitant is ongoing, with studies focusing on its efficacy, safety, and potential side effects. As a neurokinin-1 receptor antagonist, it is part of a class of drugs that are being explored for their ability to improve the quality of life for patients undergoing [[cancer treatment]]. | |||
* [[ | ==Related pages== | ||
* [[ | * [[Neurokinin-1 receptor antagonist]] | ||
* [[Chemotherapy-induced nausea and vomiting]] | |||
* [[Substance P]] | * [[Substance P]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category: | [[Category:Antiemetics]] | ||
Latest revision as of 11:00, 15 February 2025
Overview[edit]
Burapitant is a chemical compound that acts as a neurokinin-1 receptor antagonist. It is primarily researched for its potential use in treating conditions such as nausea and vomiting, particularly those induced by chemotherapy.
Chemical Structure[edit]
Burapitant is characterized by its unique chemical structure, which allows it to effectively bind to and inhibit the neurokinin-1 receptor. This receptor is involved in the body's response to stress and pain, making Burapitant a compound of interest in the development of new therapeutic agents.
Mechanism of Action[edit]
Burapitant works by blocking the action of substance P, a neuropeptide that binds to the neurokinin-1 receptor. By inhibiting this interaction, Burapitant can reduce the symptoms associated with emesis and potentially other conditions mediated by substance P.
Potential Applications[edit]
The primary application of Burapitant is in the management of chemotherapy-induced nausea and vomiting (CINV). It may also have potential uses in treating other conditions where substance P is implicated, such as certain types of pain and depression.
Research and Development[edit]
Research into Burapitant is ongoing, with studies focusing on its efficacy, safety, and potential side effects. As a neurokinin-1 receptor antagonist, it is part of a class of drugs that are being explored for their ability to improve the quality of life for patients undergoing cancer treatment.
